博九娱乐网

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor…More for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection.